> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca’s Bydureon OK’d for Pediatric Diabetics
- URL: https://www.fdaweb.com/astrazenecas-bydureon-okd-for-pediatric-diabetics/
- Published: 2021-07-23T12:00:00.000Z
- Updated: 2026-09-14T17:07:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149778

FDA has approved AstraZeneca’s Bydureon and Bydureon BCise (exenatide extended-release) injection for use in addition to diet and exercise to improve glycemic control in pediatric patients 10 years or older with Type 2 diabetes. Previously, the drug was approved for treating adults with Type 2 diabetes.

Approval was based on data from a 24-week, placebo-controlled study in pediatric patients 10 years or older. At week 24, patients receiving exenatide extended-release had an average 0.25% decrease in blood glucose measurements, whereas patients receiving the placebo had an average 0.45% increase, an [FDA release](https://content.govdelivery.com/accounts/USFDA/bulletins/2e98d66?ref=fdaweb.com) says.  

The agency says exenatide extended-release is not recommended as a first treatment option for patients whose disease is not adequately controlled through diet and exercise. It should also not be used for Type 1 diabetes.